Kidney Cancer

Different combinations of immunotherapy with chemotherapy are helping patients with renal cell carcinoma live longer.

The first study to look at cancer prevalence in transgender people and examine the health of transgender cancer survivors also found concerning health trends among transgender women and gender nonconforming people.

Young Investigator and Advanced Discovery Awards will advance kidney cancer research, as the Kidney Cancer Association opens up its grant applications.

African American race was associated with longer survival in non-clear cell metastatic renal cell carcinoma compared with Hispanic and Caucasian patients.

From New Jersey Governor Phil Murphy announcing he will undergo surgery to remove a potentially cancerous tumor on his kidney to an NHL team granting a 15-year-old fan with cancer the ultimate wish, here’s what is making headlines in the cancer space this week.

Utilizing the data of the CheckMate 9ER trial, researchers believe that combination therapies in the treatment of patients with renal cell carcinoma are the future of the landscape.

Here’s a look at what’s inside our 2020 Winter issue.

Treatments for renal cell carcinoma are showing effectiveness in the short term, but with the help of new trials, researchers are looking to expand their impact for long term treatment.

The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.

MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.

After five years of follow-up, treatment with Opdivo in those with previously treated advanced or metastatic renal cell carcinoma induced superior survival outcomes.

More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy.

Children with higher birth weight and body mass index, as well as taller height, are at a greater risk of developing renal cell carcinoma later in life, according to new study findings.

Findings from a recent study supported further evaluation of comparing anti–PD-1 to anti–PD-L1 therapy to help determine treatment options for patients with cancer.

Personalized treatments have changed the cancer landscape, and continue to change it for patients with renal cell carcinoma.

A physician’s social network is important to determining the adoption of high-value cancer drugs, as researchers have determined peer influence had a strong association with the adoption of Avastin among oncologists across the nation.

Doing a few hours of exercise per week can help prevent kidney, liver, endometrial, colon and breast cancers, as well as multiple myeloma and non-Hodgkin lymphoma, a large study found.

The Food and Drug Administration approved the first generic for Afinitor, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

A phase 3 clinical trial investigating Fotivda improved chances of preventing disease progression in patients with kidney cancer compared with Nexavar.

Here is a list of clinical trials that are currently happening within the kidney cancer space.

In cancer clinical trials, the goal, or primary endpoint, is often focused on overall survival. However, one expert from the Dana Farber Cancer Institute thinks treatment-free survival should also be documented to provide patients with the data they need to make informed treatment choices.

When asked about the future of renal cell carcinoma (RCC) treatment, one expert is hopeful about the current search, but notes that more work is needed to find a reliable biomarker for use in patients with the most common kind of kidney cancer.

The field of kidney cancer treatment could soon be expanding thanks to the inclusion of PARP inhibitors, vaccination-based strategies and emerging therapies such as Fotivda (tivozanib), according to research presented at the 2019 Kidney Cancer Research Summit.

Dr. Camillo Porta discussed what is new in kidney cancer beyond the first line of treatment at A Vision of Hope: A Kidney Cancer Educational Symposium.

Drug duos that hit kidney cancer with immunotherapy and targeted treatment offer a better alternative to single agents.

Those with non-clear cell kidney cancer have much to look forward to as oncologists’ understanding of the disease is evolving.

Pre- and post-surgical treatment could benefit patients with kidney cancer who are at high risk for disease recurrence.

One patient advocate explained how patients with renal cell carcinoma can query about clinical trials and what they need to know about them to do so.

Nutrition plays a key role in kidney cancer; however, the need to address it is still unmet.